ANVS
Annovis Bio, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Annovis Bio, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Annovis Bio, Inc.
1.14
+0.12 · +11.86%
post 1.13 −0.96%
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Annovis Bio, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Annovis Bio, Inc..
Annual filing, covered
10-K parsed · Mar 13 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 13 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
—
—
| Manager | Value | % base | |
|---|---|---|---|
| Empery | $4.5M | 19.89% | new |
| Marshall Wace | $3.4M | 15.26% | +55.14% |
| Vanguardindex-like | $3.1M | 13.64% | +88.83% |
| Tudor Investment Corp ET AL | $2.5M | 11.24% | new |
| Renaissance Technologies | $1.9M | 8.30% | +188.32% |
| Manager | Value | % base | |
|---|---|---|---|
| Empery | $4.5M | 19.89% | new |
| Marshall Wace | $3.4M | 15.26% | +55.14% |
| Vanguardindex-like | $3.1M | 13.64% | +88.83% |
| Tudor Investment Corp ET AL | $2.5M | 11.24% | new |
| Renaissance Technologies | $1.9M | 8.30% | +188.32% |
Bull1
Bear1
Expected move
No implied move.